BACKGROUND: Anti-RhD administration can prevent de novo anti-RhD formation following RhD+ red blood cell (RBC) exposure, termed antibody-mediated immunosuppression (AMIS). Recent studies suggest that AMIS may occur through target antigen alterations, known as antigen modulation. However, studies suggest that AMIS may occur independent of antigen modulation. In particular, AMIS to RBCs that transgenically express the fusion hen egg lysozyme-ovalbumin-Duffy (HOD) antigen have been shown to occur independent of activating Fcγ receptors (FcγRs) thought to be required for antigen modulation. Therefore, we sought to determine the mechanism behind AMIS following HOD RBC exposure.
RESULTS: Our results demonstrate that anti-HEL antibodies individually or in combination suppressed anti-HOD IgM, which correlated with the rate of detectable decrease in HEL on HOD RBCs. Furthermore, exposure to anti-HEL antibodies alone or in combination equally suppressed anti-HOD IgG formation. Unexpectedly, combination or individual anti-HEL antibodies induced AMIS and antigen modulation in an FcγR-independent manner. Pre-exposure of HOD RBCs to anti-HEL antibodies reduced antigen levels and suppressed anti-HOD antibody formation following HOD RBC exposure.
CONCLUSION:
These results suggest that antibodymediated antigen modulation may reflect a mechanism of AMIS that can occur independent of activating FcγRs and may provide a surrogate to identify antibodies capable of inducing AMIS against different RBC antigens.
A ntibodies to distinct red blood cell (RBC) antigens that develop following transfusion or pregnancy can lead to hemolytic disease of the fetus and newborn. [1] [2] [3] [4] Currently, the only commercially available prophylaxis that can actively prevent anti-RBC antibody development following antigen exposure is Rh immune globulin (RhIg). [5] [6] [7] [8] [9] [10] RhIg, polyclonal anti-RhD generated from pooled donor serum administered to prevent de novo anti-D development, is the most commonly employed example of antibody-mediated immunosuppression (AMIS). As the availability of RhIg donors is limited and the only available immunoprophylaxis is against RhD, there is a critical need to develop monoclonal antibody alternatives to RhIg and immunoprophylaxis to other RBC antigens. As different monoclonal antibodies to the RhD antigen can have differential immunological outcomes, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] understanding the mechanism regarding how monoclonal antibodies induce AMIS can facilitate the development and accurate assessment of monoclonal antibodies against RhD and other RBC antigens.
While the mechanisms responsible for RhIg-induced AMIS remain unknown, several hypotheses have been suggested, including rapid clearance and/or steric hindrance of RhD+ RBCs to prevent B-cell recognition or direct immune modulation. [21] [22] [23] However, as RBC clearance rates do not necessarily correspond to the ability of an antibody to induce AMIS 23 and several studies suggest that steric hindrance or inhibition of the immune response through inhibitory Fcγ receptors (FcγRs) may not play a role in AMIS, [24] [25] [26] [27] [28] alternative mechanisms may be responsible. Recent studies using the KEL model system demonstrate that AMIS to the KEL RBC antigen correlates with antigen modulation, 29, 30 a phenomenon referring to antibody-induced loss of the target RBC antigen. In this setting, anti-KEL antibodies induce complement fixation and subsequent antigen modulation, which was found to be dependent on both complement and activating FcγRs. [31] [32] [33] [34] [35] [36] Similarly, previous studies demonstrate that FcγRs are also required for anti-HEL (hen egg lysozyme) antibody-induced antigen loss following engagement of the HEL antigen expressed in a membrane-bound form on RBCs (mHEL RBCs). 36 However, when HEL is expressed along with ovalbumin and human Duffy as a fusion protein on RBCs (HOD RBCs), AMIS to HOD occurs independent of FcγRs, 28 suggesting that anti-HEL-induced AMIS following HOD RBC exposure may occur independent of antigen modulation. These collective data suggest that while antigen modulation may mediate anti-KEL-induced AMIS, anti-HEL antibodies likely induce AMIS to the HOD antigen through an alternative mechanism. Furthermore, while previous studies have separately examined monoclonal antibodymediated AMIS to the HOD alloantigen and the role of FcγRs in antigen modulation of HEL on mHEL RBCs, 27, 36, 37 no studies have formally examined whether monoclonal anti-HELs antibodies mediate antigen modulation to the HOD antigen. Therefore, we sought to determine whether AMIS to HOD RBCs occurs via monoclonal antibody-induced antigen modulation.
To study this, we used the previously established HOD RBC model to define the impact of potential changes in surface RBC antigen as a mechanism responsible for AMIS. 27, 28, 38, 39 Our results demonstrate that monoclonal anti-HEL antibodies individually or in combination inhibit the downstream antibody response to HOD RBCs, in support of previous findings. 27 Anti-HEL-induced AMIS not only correlated with a decrease in the level of detectable HEL antigen on the RBC surface, but both antigen modulation and AMIS occurred independent of activating FcγR function. Together, these data suggest that monoclonal antibodies may inhibit antibody responses to some RBC antigens through FcγR-independent modulation of the target antigen.
MATERIALS AND METHODS
Mice C57BL/6 (B6) mice were purchased from Charles River and Fcer1g (FcγR KO) mice deficient in the common gamma chain were purchased from Taconic Laboratories. HOD transgenic mice were generated as previously described. 39 Emory Division of Animal Resources and Husbandry bred and housed the mice used in these experiments. Male and female mice were used at ages 8 to 12 weeks. The experimental protocols and animal procedures performed in these studies were approved by the Emory University Institutional Animal Care and Use Committee.
RBC labeling and transfusion
HOD+ and HOD− control RBCs were collected and labeled as previously described. 37 
RESULTS

Monoclonal anti-HEL antibodies decrease antibody formation and detectable antigen
We used a previously established model of AMIS wherein B6 recipients are exposed to HOD RBCs in the presence or absence of saturating concentrations of 2F4 and 4B7 anti-HEL monoclonal antibodies individually or in combination (Fig. 1A) , each of which recognize distinct HEL epitopes (Fig. 1B) . 27, 42 Consistent with previous studies in which anti-HOD IgM is detectable 3 to 5 days after transfusion of HOD RBCs and class switching to IgG occurring between days 7 and 14 after transfusion, 43, 44, 49, 50 exposure to HOD RBCs resulted in an anti-HOD IgM and IgG response, with no development of anti-HOD antibodies in HOD mice exposed to HOD RBCs (Fig. 1B) . However, when HOD RBCs were transfused in the presence of anti-HEL antibodies, individually or in combination, the anti-HOD IgM response was blunted on Day 5 after transfusion (Fig. 1B) . Furthermore, the anti-HOD IgG response was also suppressed in the presence of a combination or individual monoclonal antibodies (Fig. 1B) . To determine whether antibody engagement differed over time, mice were exposed to labeled HOD RBCs, and RBCs were analyzed by a flow cytometry-based direct antiglobulin test (DAT) ( Fig. 2A,B) . The DAT revealed that IgG could be detected directly on HOD RBCs in the presence of anti-HEL antibodies at 10 minutes and 2 hours after transfusion ( Fig. 2C and D) . However, exposure to a combination of monoclonal anti-HEL antibodies resulted in a more rapid decrease in DAT levels than anti-HEL antibodies individually, with DAT levels decreasing through 5 days after transfusion ( Fig. 2E-H ). While polyclonal antibodies have been shown to induce modulation of the HEL antigen on mHEL RBCs, 36, 41 monoclonal antibodies alone were not found to induce alterations to the target antigen, 42 suggesting that the loss of detectable antibody on the HOD RBC surface over time may reflect antibody dissociation. To test this, the level of detectable antigen was examined over time ( Fig. 1) , 43, 44, 49, 50 suggesting that development of de novo anti-HEL antibodies in B6 mice exposed to HOD RBCs may also induce changes in the level of detectable HEL antigen over time.
AMIS can occur independently of activating FcγR function
Given that our findings thus far indicate that monoclonal antibody-induced AMIS to HOD RBCs may occur as a result of changes in the level of detectable HEL antigen in B6 mice and that AMIS induced by antibody-mediated antigen modulation of the HEL antigen on mHEL RBCs occurs through an FcγR-mediated process, 36, 40 we tested the role of activating antibodies individually did not experience an initial decrease in their level of detectable HEL antigen at 10 minutes after transfusion (Fig. 4A ), but began to display decreases in detectable antigen 2 hours after transfusion (Fig. 4B) . By Day 1 after transfusion, HEL antigen levels on HOD RBCs in FcγR KO mice exposed to individual monoclonal antibodies began to significantly decline over time ( Fig. 4C-F) . Similar to the decrease in detectable HEL antigen observed in B6 mice, reductions in HEL antigen levels in FcγR KO recipients exposed to HOD RBCs with monoclonal anti-HEL antibodies were also found to correlate with decreases in detectable antibody on the RBC surface. By 10 minutes after transfusion, IgG antibody was detectable on the HOD RBC surface in FcγR KO mice exposed to HOD RBCs in the presence of monoclonal anti-HEL antibodies, individually or in combination (Fig. 5A ). However, from 2 hours through Day 5 after transfusion, the level of IgG antibody deposited on the HOD RBC surface decreased in FcγR KO mice that received HOD RBCs in the presence of monoclonal anti-HEL antibodies, individually or in combination (Fig. 5B-F) . This decrease in bound IgG on the HOD RBC surface paralleled the decrease in detectable HEL antigen (Fig. 4) . Given the ability of monoclonal anti-HEL antibodies to decrease the level of detectable HEL antigen in B6 and FcγR KO mice, and as the decrease in antigen level correlated with AMIS in B6 mice (Figs. 1-4) , we tested whether AMIS likewise occurred in FcγR KO mice. Exposure of FcγR KO mice to HOD RBCs in the absence of monoclonal anti-HEL antibodies resulted in the development of anti-HOD IgM and IgG at Days 5 and 14 after transfusion, respectively. However, exposure of FcγR KO mice to HOD RBCs in the presence of monoclonal anti-HEL antibodies resulted in equivalent inhibition of anti-HOD IgM and IgG formation (Fig. 6A ). Similar to HOD RBC transfusion into B6 mice, monoclonal anti-HEL antibodies failed to fix detectable complement or alter HOD RBC clearance in FcγR KO mice (Fig. 6B and C) . 
Retransfusion of antigen-modulated HOD RBCs affects subsequent anti-HOD response
The dampened anti-HOD IgM response observed following exposure to monoclonal anti-HEL antibodies individually or in combination correlated with the decrease in detectable HEL antigen in B6 mice exposed to HOD RBCs in the presence of monoclonal anti-HEL antibodies, which may reflect early alterations in the availability of HEL antigen observed following exposure to anti-HEL antibodies individually or in combination. Homozygous and heterozygous HOD mice exhibit no detectable differences in HEL antigen expression (Fig. 7A) , precluding direct examination of the potential impact of antigen density in the absence of antibody-induced changes in antigen levels. Therefore, to more directly test this, B6 mice were first exposed to HOD RBCs in the presence or absence of monoclonal anti-HEL antibodies to reach varying levels of antigen reduction. Using this approach, HOD RBCs were followed for changes in the level of detectable HEL antigen until a 50% or 90% reduction in HEL antigen on RBCs in the presence of monoclonal anti-HEL antibodies individually or in combination occurred (Fig. 7B) , respectively, to approximate the level of detectable antigen observed on HOD RBCs 1 day after antibody exposure (Fig. 3D ). RBCs were then harvested and re-transfused into naïve B6 recipients, followed by evaluation of the detectable HEL antigen over time to determine whether the HEL antigen further decreased in retransfused mice. At 10 minutes and Day 1 after transfusion, the level of detectable HEL antigen on retransfused HOD RBCs that were previously exposed to individual monoclonal anti-HEL antibodies remained stable (Fig. 7C and D) . However, by Day 3 after retransfusion, the level of detectable HEL antigen decreased on the HOD RBCs that previously circulated in the presence of monoclonal anti-HEL antibodies individually (Fig. 7E) . The level of detectable HEL antigen on HOD RBCs that were exposed to a combination of anti-HEL monoclonal antibodies remained low from 10 minutes through Day 5 after retransfusion (Fig. 7C-F) . Re-transfusion of HOD RBCs with decreased antigen due to prior exposure to anti-HEL monoclonal antibodies individually or in combination resulted in an equally dampened anti-HOD response (Fig. 7G) . The similar ability of individual or combinations of anti-HEL antibodies to induce AMIS did not appear to reflect differences in HOD RBC clearance following re-transfusion, as no change in HOD RBC clearance was observed following retransfusion (Fig. 7H) .
HEL antigen decreases as HOD RBCs age
Given the ability of monoclonal antibodies to impact HEL antigen levels following HOD RBC exposure in FcγR KO mice, it remained possible that anti-HEL antibodies simply enhance an existing process of antigen removal on HOD RBCs. This is especially relevant when considering that antigens are not resynthesized on mature RBCs, and therefore certain RBC antigens may be more susceptible to degradation over time. Consistent with this, HEL antigen levels were consistently lower than the Duffy antigen on RBCs harvested from HOD mice (Fig. 8A) , suggesting that HEL may be uniquely sensitive to degradation over time. To initially determine whether the HEL antigen may be more sensitive to proteolytic cleavage, HOD RBCs were incubated with a range of protease concentrations (Fig. 8B) . HEL antigen displayed more sensitivity toward proteolytic cleavage than Duffy or Ter-119 antigens, which failed to experience similar changes in levels under the same conditions ( Fig. 8C-E) . However, inclusion of anti-HEL antibodies failed to alter the differential sensitivity of HEL to proteolytic cleavage ( Fig. 8B-E) . As a result, we next sought to simply determine whether HEL is selectively lost over time on HOD RBCs as they age in vivo in the absence of anti-HEL antibodies. To accomplish this, HOD RBC donor mice were biotinylated, followed by tracking HOD RBCs over time (Fig. 8F) . While biotinylation itself failed to impact the level of detectable HEL, Duffy, or Ter-119, by 14 days after biotinylation, the level of HEL decreased. In contrast, similar changes failed to occur in Duffy or Ter-119 when evaluated in parallel (Fig. 8G-I) . Despite the inability of anti-HEL antibodies to impact HEL antigen sensitivity to proteolytic cleavage in vitro, we next sought to determine whether selective loss of HEL likewise occurs following antibody-mediated HEL antigen removal (Fig. 8J) . HEL antigen on HOD RBCs experienced a 50% or 90% decrease in the presence of monoclonal anti-HEL antibodies, individually or in combination, respectively (Fig. 8K ) with no detectable change in Duffy antigen (Fig. 8L) . Despite the absence of detectable complement fixation on the RBC surface (Fig. 3H) , it remained possible that antibody fragments may mask the HEL antigen, resulting in apparent HEL antigen loss. To test this, western blot analysis was performed. Using this approach, HEL antigen loss was observed following exposure to monoclonal anti-HEL antibodies individually or in combination (Fig. 8M) . Taken together, these results suggest that anti-HEL antibodies may accelerate an existing process of HEL antigen removal.
DISCUSSION
In this study, monoclonal anti-HEL antibodies were not only found to correlate with a dampened IgM antibody response to the HOD RBC antigen, but also a decreased level of detectable HEL antigen. These findings suggest that monoclonal antibodies may induce AMIS by decreasing detectable HEL antigen levels below the threshold necessary to activate HEL-reactive B cells. B cell activation typically requires not only a threshold concentration of antigen, but also a threshold of receptor stimulation. [51] [52] [53] [54] [55] [56] Consistent with this, lowering the level of detectable HEL antigen by 50% resulted in an equivalent degree of IgM suppression. As no difference in the anti-HOD IgG response was observed whether HOD RBCs were transfused in the presence of monoclonal anti-HEL antibodies alone or in combination, the similar level of IgG suppression suggests that by the time class switching occurs, HEL antigen levels may have dropped below the threshold needed to efficiently induce anti-HEL IgG. As suppression of IgG antibody formation is the primary target of immunoprophylaxis, these results suggest that monoclonal IgG antibodies that initially only partially induce antigen loss may be sufficient for equivalent inhibition of IgG formation. As the consequence of antibody-antigen interactions can differ, the requirements of AMIS for a particular antigen may likewise uniquely depend on the target antigen. For example, the reduced efficacy of monoclonal antibodies to induce AMIS toward RhD may in part reflect a need for multiple antibodies to induce antigen modulation, 24 ,58 as demonstrated for HEL antigen expression on mHEL RBCs. 42 Although recent studies demonstrate that anti-RhD can induce antigen modulation clinically, 59 it is certainly possible that for RhD and possibly other antigens, a combination of RBC clearance and antigen modulation collectively contribute to AMIS. As anti-RhD represents the only clinically available AMIS intervention, understanding potential differences in the outcome of antibody engagement of a variety of RBC antigens is important in understanding both common and distinct features of antibody-antigen interactions that may result in AMIS. 28, 29, [36] [37] [38] [40] [41] [42] 47, 48, 57 Such information will likely prove vital for rational approaches to be developed to target other antigens for which no immunoprophylaxis currently exists. In addition to a potential threshold of detectable HEL antigen necessary to induce a productive anti-HOD antibody response, the rate at which the HEL antigen is modulated may likewise impact the development of anti-HOD antibodies. Given that HOD RBCs in the presence of monoclonal anti-HEL antibodies undergo a more rapid decrease in the level of detectable HEL antigen than HOD RBCs transfused into B6 recipients in the absence of monoclonal anti-HEL antibodies, the removal of antigen at early time points may prevent sufficient detection and therefore response to HOD at these earlier time points. Actual differences or trends toward reduced ability of individual monoclonal antibodies to suppress anti-HOD IgM may likewise reflect distinct windows wherein antigen substrate is needed for anti-HOD IgM formation in contrast to the possibility of slightly later antigen requirements for IgG antibody formation. While the ability of anti-HEL antibodies to modulate antigen suggests that such thresholds exist, the exact threshold requirements for productive antibody formation remain unknown. Unfortunately, as antibody provided the only mechanism of selectively removing HEL from HOD RBCs, we cannot rule out the potential impact of antibody remaining on the cell surface on antibody formation. While proteolytic cleavage allowed HEL to be selectively removed in vitro, many proteins are sensitive to protease, 60 which could impact RBC circulatory half-life, interactions with immune cells or other RBC changes that may influence the overall immune response to HOD, precluding the use of this approach to examine the potential impact of HEL antigen levels on anti-HOD formation. HOD founders that express different levels of HOD, as recently described for KEL, 46 will ultimately be needed to begin defining potential antigen threshold requirements for a productive immune response against the HOD antigen. While antigen removal still occurred in FcγR KO recipients, the rate of antigen modulation was reduced compared to B6 mice, suggesting that while antigen modulation and AMIS can occur independent of FcγRs, these receptors may contribute to early antigen removal. Consistent with this, previous studies indicate that FcγRs can facilitate antigen removal. 40, 41 However, given that previous studies have refuted the involvement of both activating and inhibitory FcγRs in polyclonal antibody-mediated AMIS to HOD RBCs, 28 and our study shows that the monoclonal anti-HEL antibodies do not fix complement nor are activating FcγRs required for AMIS or antigen modulation to occur, these studies therefore suggest a novel mechanism of antigen removal distinct from those previously described. 29 in the absence of monoclonal anti-HEL anti-bodies. However, it is important to note that increased sensitivity of HEL to proteolytic cleavage in vitro may not reflect antibody-induced loss of the HEL antigen in vivo, which may instead represent an entirely different process. Distinct mechanisms of antigen modulation may play unique roles in different antigen systems, each of which may be differentially sensitive to variables such as saturation, involvement of antibody effector systems and level of antibody antigen engagement required. Although antibody-induced antigen loss has been documented in various settings in both animal models and humans, 30, 40, 48, 59, 68, 69 the underlying mechanisms whereby these processes occur remain to be determined. As with all experimental models, limitations must be considered. In this study, we examine one particular RBC antigen in combination with two monoclonal anti-HEL antibodies previously validated to induce AMIS in this model system. 27 Therefore, while both monoclonal anti-HEL antibodies tested induced antigen modulation and recent studies demonstrate that monoclonal antibodies that target RBC antigens can induce antigen loss in patients, 48, 59 whether antigen modulation is a general phenomenon that occurs following antibody engagement of other RBC antigens remains to be determined. Furthermore, despite lack of analysis of Duffy antigen by western blot analysis, loss of the HEL antigen by western blot analysis, coupled with similar loss of HEL detection by flow cytometric analysis in the absence of similar changes in Duffy antigen levels, suggests that anti-HEL antibodies induce selective antigen removal. While preclinical models possess limitations, these models allow us to investigate potential molecular mechanisms whereby general principles of AMIS may occur. As the KEL and HOD models are the only systems published to date that render themselves to AMIS studies, these findings suggest that antigen modulation may play a role in AMIS. However, whether this approach actually prevents alloimmunization against other RBC antigens remains to be tested. Using this and related model systems may therefore provide important insight when seeking to answer questions in transfusion medicine surrounding the development of antibodies capable of inducing AMIS.
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